Viridian CEO updates Form 4 tax share disposal

Viridian Therapeutics President and CEO Stephen F. Mahoney disposed of 7,408 shares of common stock on March 3, 2026 at $30.19 per share to cover taxes.

Accepted by SEC EDGAR 03/09/2026 - 07:35 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Viridian Therapeutics President and CEO Stephen F. Mahoney disposed of 7,408 shares of common stock on March 3, 2026 at $30.19 per share to cover taxes. This amended Form 4 corrects the share and price figures previously reported and shows he beneficially owns 33,349 shares afterward.

Insider Trade Summary

Exercise Price or Tax Liability: 7,408 shares

Exercise Price or Tax Liability 1 txn

Insider Mahoney Stephen F.

Role President and CEO

Type	Security	Shares	Price	Value
Exercise Price or Tax Liability	Common Stock	7,408	$30.19	$224K

Holdings After Transaction: Common Stock — 33,349 shares (Direct)

Holdings Before and After: Common Stock, 40,757 to 33,349 shares (Direct)

Footnotes (1)

1. F1. This amendment corrects the number of shares and price sold to cover taxes on the initial Form 4 filed on March 4, 2026, as well as the resulting total number of shares beneficially owned following all transactions reported in the initial Form 4.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Viridian Therapeutics (VRDN) CEO Stephen Mahoney report in this Form 4/A?

Stephen Mahoney reported a tax-withholding disposition of 7,408 Viridian Therapeutics shares at $30.19 on March 3, 2026. The amended filing corrects prior figures and shows he beneficially owns 33,349 shares following the transaction.

Why did Viridian Therapeutics (VRDN) CEO dispose of 7,408 shares?

The 7,408 shares were sold to cover tax obligations related to equity compensation. This is coded as a tax-withholding disposition, meaning shares were used to pay taxes rather than an open-market sale for investment purposes.

What does this amended Form 4/A change for Viridian Therapeutics (VRDN)?

The amended Form 4/A corrects the number of shares and price previously reported as sold to cover taxes. It also updates the total beneficial ownership figure to 33,349 shares following all transactions in the original Form 4.

How many Viridian Therapeutics (VRDN) shares does the CEO own after this transaction?

After the tax-withholding disposition, Stephen Mahoney is reported to beneficially own 33,349 shares of Viridian Therapeutics common stock. This total reflects corrections made in the amended Form 4 to earlier reported amounts.

Was this Viridian Therapeutics (VRDN) CEO transaction an open-market sale?

No. The transaction is classified as a tax-withholding disposition under code F, meaning shares were withheld or sold to satisfy tax liabilities, not executed as a discretionary open-market sale for portfolio reasons.

What is the significance of transaction code F in the Viridian (VRDN) filing?

Transaction code F indicates payment of a tax liability by delivering securities. In this case, 7,408 shares were used to cover taxes tied to equity compensation, rather than representing a traditional buy or sell decision in the market.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Mahoney Stephen F.

(Last) (First) (Middle)

C/O VIRIDIAN THERAPEUTICS, INC.

221 CRESCENT STREET, SUITE 103A

(Street)

WALTHAM MA 02453

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Viridian Therapeutics, Inc.\DE [ VRDN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

3. Date of Earliest Transaction (Month/Day/Year)
03/03/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)
03/04/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/03/2026		F		7,408(1)	D	$30.19	33,349(1)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This amendment corrects the number of shares and price sold to cover taxes on the initial Form 4 filed on March 4, 2026, as well as the resulting total number of shares beneficially owned following all transactions reported in the initial Form 4.

	/s/Jennifer Tousignant, Attorney-in-fact	03/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.